Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Gynae 2023 | Selecting patients to be treated with maintenance olaparib in the PAOLA-1 trial

Eric Pujade-Lauraine • 20 Feb 2023
ESMO Gynae 2023
Gynecological Cancer Ovarian Cancer Bevacizumab Olaparib
PAOLA-1

Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, discusses how to best select ovarian cancer patients who will benefit best from PARP inhibition, highlighting the results of the PAOLA-1 trial (NCT02477644) which evaluated maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer. This interview took place at the ESMO Gynaecological Cancers Congress 2023 in Barcelona, Spain

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eric Pujade-Lauraine

0:48
Immune checkpoint inhibitors in ovarian cancer
Eric Pujade-Lauraine • 24 Oct 2021
3:06
Results from the JAVELIN Ovarian 200 biomarker analysis
Eric Pujade-Lauraine • 24 Oct 2021
1:06
Improving immunotherapy outcomes in ovarian cancer
Eric Pujade-Lauraine • 24 Oct 2021
2:50
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
Eric Pujade-Lauraine • 26 Sep 2015

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals